Clinical Trial Update: Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of deferasirox and erythropoietin in patients with low- and int-1-risk myelodysplastic syndrome has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Deferasirox (Deferasirox)
• Erythropoietin (erythropoietin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Low and Int 1-risk Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2018-10-31